The Technical Analyst
Spruce Biosciences, Inc. [SPRB]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Spruce Biosciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.11% $0.701
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 28.85 mill |
| EPS: | -1.240 |
| P/E: | -0.570 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 41.15 mill |
| Avg Daily Volume: | 1.367 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.570 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.10x |
| Company: PE -0.570 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.411 - 0.991 ( +/- 41.37%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-21 | Novo Holdings A/s | Sell | 465 021 | COMMON STOCK |
| 2024-03-18 | Novo Holdings A/s | Sell | 842 020 | COMMON STOCK |
| 2024-03-19 | Novo Holdings A/s | Sell | 593 000 | COMMON STOCK |
| 2024-03-20 | Novo Holdings A/s | Sell | 359 979 | COMMON STOCK |
| 2024-03-14 | Novo Holdings A/s | Sell | 1 912 316 | COMMON STOCK |
| INSIDER POWER |
|---|
| 2.86 |
| Last 98 transactions |
| Buy: 11 294 782 | Sell: 4 967 660 |
Forecast:
16:00 - $0.710
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.710
Forecast 2: 16:00 - $0.710
Forecast 3: 16:00 - $0.710
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.701 (-0.11% ) |
| Volume | 0.377 mill |
| Avg. Vol. | 1.367 mill |
| % of Avg. Vol | 27.61 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SPRB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 12 - 11:21 | buy | $4.40 | N/A | Active |
|---|
SPRB
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-22 16:05:00 - Press Release
Spruce Biosciences Announces Upcoming Poster Presentation At The Pediatric Endocrine Society 2024 Annual Meeting
South san francisco, calif.--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the pediatric endocrine society (pes) 2024 annual meeting taking place may 2-5, 2024, in chicago, il. in the poster presentation, paul thornton, m.b.b.s., will highlig.
2024-04-19 04:00:00 - Press Release
Important Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Spruce Biosciences, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 19, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of spruce biosciences, inc. ("spruce" or "the company") (nasdaq:sprb) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-04-05 07:00:00 - Press Release
Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Spruce Biosciences, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 5, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of spruce biosciences, inc. ("spruce" or "the company") (nasdaq:sprb) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-04-04 19:15:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Spruce Biosciences, Inc. - Sprb
New york , april 4, 2024 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of spruce biosciences, inc. ("spruce" or the "company") (nasdaq: sprb). such investors are advised to contact danielle peyton at newaction@pomlaw.com or 646-581-9980, ext.
2024-04-04 07:00:00 - Press Release
Ongoing Shareholder Alert: The Schall Law Firm Announces It Is Investigating Claims Against Spruce Biosciences, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 4, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of spruce biosciences, inc. ("spruce" or "the company") (nasdaq:sprb) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Latest News
2024-03-27 13:01:18 - Zacks Investment Research
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-03-21 11:21:04 - Zacks Investment Research
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
Spruce Biosciences' (SPRB) CAHmelia-203 phase IIb study of tildacerfont in adult patients with CAH fails to meet the primary efficacy endpoint.
2024-03-14 08:28:50 - InvestorPlace
Why Is Spruce Biosciences (SPRB) Stock Down 78% Today?
Spruce Biosciences (NASDAQ: SPRB ) stock is falling hard on Thursday after the biopharmaceutical company posted two new updates for investors. The first big update that has investors in SPRB stock reeling are the results of a Phase 2b clinical trial of tildacerfont in adult patients with classic congenital adrenal hyperplasia ( CAH ).
2024-01-30 16:05:00 - Business Wire
Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 2:40 p.m. ET. Interested parties can access the live webcast here.
2023-10-20 08:15:02 - Benzinga
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2023-08-28 16:00:00 - Business Wire
Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET. Interested parties can access the live webcast here.
2023-02-23 11:54:47 - PennyStocks
Best Penny Stocks To Buy? 3 To Watch With Targets Up To 400%
Analysts like these penny stocks but is it time to buy or not? The post Best Penny Stocks To Buy?
2023-02-09 12:07:55 - PennyStocks
Penny Stocks To Buy? 4 Cheap Stocks To Watch Right Now
2022-08-30 16:05:00 - Business Wire
Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #Tildacerfont--Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
2022-01-07 08:27:28 - Pulse2
Spruce Biosciences Stock (SPRB): Why The Price Jumped
The stock price of Spruce Biosciences Inc (NASDAQ: SPRB) increased by 13.48% in the most recent trading session. This is why it happened.